News | July 03, 2021
Solara announces restoration of CEP for ranitidine hydrochloride
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Subscribe To Our Newsletter & Stay Updated
